<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="365182">
  <stage>Registered</stage>
  <submitdate>12/05/2014</submitdate>
  <approvaldate>22/05/2014</approvaldate>
  <actrnumber>ACTRN12614000551695</actrnumber>
  <trial_identification>
    <studytitle>Efficacy and tolerability of asenapine compared with olanzapine in borderline personality disorder: a randomized controlled trial</studytitle>
    <scientifictitle>Asenapine versus olanzapine in the treatment of impulsivity, aggression, and self injuries in patients with borderline personality disorder.</scientifictitle>
    <utrn>U1111-1149-4071</utrn>
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Borderline personality disorder</healthcondition>
    <conditioncode>
      <conditioncode1>Mental Health</conditioncode1>
      <conditioncode2>Psychosis and personality disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Patients will be randomly assigned to two arms of treatment: 1) asenapine (dose range: 5-10 mg/day) or 2) olanzapine (dose range: 5-10 mg/day). All drugs will be administered daily as oral tablets. The two drugs will be titrated (for the first three days at the dose of 5 mg/day and after at the dose if 10 mg/day, if side effects do not appear). The duration of treatment will be 12 weeks.
To monitor compliance to therapy we will check drug tablet return and we will ask, when available, the cooperation of a caregiver.</interventions>
    <comparator>olanzapine at the dose of 5-10 mg/day</comparator>
    <control>Active</control>
    <interventioncode>Treatment: Drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Global symptoms assessed with the Clinical Global Impression Scale (CGI-S)</outcome>
      <timepoint>At baseline (T0) and after 6 (T1/2) and 12 (T1) weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Specific borderline symptomatology measured with the Borderline Personality Disorder Severity Index (BPDSI)</outcome>
      <timepoint>At baseline (T0) and after 6 (T1/2) and 12 (T1) weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Impulsivity assessed with the Barratt Impulsiveness Scale-version 11 (BIS-11)</outcome>
      <timepoint>At baseline (T0) and after 6 (T1/2) and 12 (T1) weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Aggressiveness measured with the Modified Overt Aggression Scale (MOAS)</outcome>
      <timepoint>At baseline (T0) and after 6 (T1/2) and 12 (T1) weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Self injurious behaviors assessed with the Self-Harm Inventory (SHI)</outcome>
      <timepoint>At baseline (T0) and after 6 (T1/2) and 12 (T1) weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Affective symptoms measured with the Hamilton Scales for depression and anxiety (HAM-D) and (HAM-A)</outcome>
      <timepoint>At baseline (T0) and after 6 (T1/2) and 12 (T1) weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Interpersonal functioning measured with the Social and Occupational Funcioning Assessing Scale (SOFAS)</outcome>
      <timepoint>At baseline (T0) and after 6 (T1/2) and 12 (T1) weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Side effects of the drugs assessed with the Dosage Record and Treatment Emergent Symptoms Scale (DOTES)</outcome>
      <timepoint>At baseline (T0) and after 6 (T1/2) and 12 (T1) weeks</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Diagnosis of borderline personality disorder</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>55</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Dementia, delirium and other cognitive disorders; schizophrenia and other psychotic disorders. Lifetime bipolar disorders. Concurrent major depressive episode. Substance abuse in the last two months.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>19/05/2014</anticipatedstartdate>
    <actualstartdate>19/05/2014</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>80</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Italy</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>Centre for Personality Disorders, Psychiatric Clinic, Department of Neuroscience, University of Turin, Italy</primarysponsorname>
    <primarysponsoraddress>Centre for Personality Disorders, Psychiatric Clinic, Department of Neuroscience, University of Turin, Via Cherasco, 11, 10126 Turin, Italy</primarysponsoraddress>
    <primarysponsorcountry>Italy</primarysponsorcountry>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>Centre for Personality Disorders, Psychiatric Clinic 1, Department of Neuroscience, University of Turin, Italy</fundingname>
      <fundingaddress>Centre for Personality Disorders, Psychiatric Clinic 1, Department of Neuroscience, University of Turin, Via Cherasco 11, 10126 Turin, Italy</fundingaddress>
      <fundingcountry>Italy</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>None</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>To date, only one open label trial on asenapine in the treatment of borderline personality disorder (BPD) is available. This study is aimed to test the efficacy and tolerability of asenapine compared with olanzapine (a widely studied antipsychotic in treatment of BPD). We will recruit consecutive patients with diagnosis of BPD. Patients will be randomly assigned to two arms of treatment: (1) asenapine (5-10 mg(day) or (2) olanzapine (5-10 mg/day). The trial duration will be 12 weeks. All participants will be tested at baseline, and after 6 and 12 weeks with the following instruments: the Clinical Global Impression Scale (CGI-S); the Borderline Personality Disorder Severity Index (BPDSI); the Barratt Impulsiveness Scale - version 11 (BIS-11); the Modified Overt Aggression Scale (MOAS); the Self-Harm Inventory (SHI); the Social and Occupational Functioning Assessment Scale (SOFAS); and the Dosage Record and Treatment Emergent Symptom Scale (DOTES).</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Comitato Etico interaziendale A.O.U. SAN GIOVANNI BATTISTA DI TORINO, A.O. C.T.O./ MARIA ADELAIDE DI TORINO</ethicname>
      <ethicaddress>Corso Bramante 88/90 10126, Turin</ethicaddress>
      <ethicapprovaldate>20/01/2014</ethicapprovaldate>
      <hrec>0005565</hrec>
      <ethicsubmitdate>25/10/2013</ethicsubmitdate>
      <ethiccountry>Italy</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Prof</title>
      <name>Silvio Bellino</name>
      <address>Department of Neuroscience, Psychiatric Clinic, University of Turin, Via Cherasco 11, 10126, Turin, Italy.</address>
      <phone>+39 011-6634848</phone>
      <fax>+39 011-673473</fax>
      <email>silvio.bellino@unito.it</email>
      <country>Italy</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Silvio Bellino</name>
      <address>Department of Neuroscience, Psychiatric Clinic, University of Turin, Via Cherasco 11, 10126, Turin, Italy.</address>
      <phone>+39 0116634848</phone>
      <fax>+39 011673473</fax>
      <email>silvio.bellino@unito.it</email>
      <country>Italy</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Paola Bozzatello</name>
      <address>Department of Neuroscience, Psychiatric Clinic, University of Turin, Via Cherasco 11, 10126, Turin, Italy.</address>
      <phone>+39 011665425</phone>
      <fax>+39 011673473</fax>
      <email>paola.bozzatello@unito.it</email>
      <country>Italy</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>La Spina Alberto</name>
      <address>Department of Neuroscience, Psychiatric Clinic, University of Turin, Via Cherasco 11, 10126, Turin, Italy.</address>
      <phone>+39 0116335425</phone>
      <fax>+39 011673473</fax>
      <email>silvio.bellino@unito.it</email>
      <country>Italy</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>